Roxithromycin Sandoz® (Tablets) Instructions for Use
ATC Code
J01FA06 (Roxithromycin)
Active Substance
Roxithromycin (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Antibiotic of the macrolide group
Pharmacotherapeutic Group
Antibiotic-macrolide
Pharmacological Action
A semisynthetic antibiotic of the macrolide group. The mechanism of action is due to the disruption of intracellular protein synthesis in microorganisms. At low concentrations, it has a bacteriostatic effect; at high concentrations, it has a bactericidal effect.
It is active against gram-positive bacteria: Streptococcus pneumoniae, Streptococcus pyogenes, methicillin-sensitive strains of Staphylococcus aureus; and against gram-negative bacteria: Moraxella catarrhalis.
Roxithromycin is also active against Mycoplasma pneumoniae, Ureaplasma urealyticum, Chlamydia spp.
The activity of roxithromycin against Haemophilus influenzae is less pronounced than that of erythromycin.
It has low activity against Mycoplasma hominis.
Pseudomonas spp., Enterobacter spp., Acinetobacter spp. are resistant to roxithromycin.
Pharmacokinetics
After oral administration, it is rapidly absorbed from the gastrointestinal tract. It is detected in the blood serum as early as 15 minutes. It is more stable in the acidic environment of the stomach than other macrolides. Food intake does not affect absorption. Cmax in blood plasma is reached in 1.5-2 hours. Css in blood plasma when taking 150 mg twice daily is reached after 2-4 days and is 9.3 mg/L; when taking 300 mg once daily, it is 10.9 mg/L.
Roxithromycin penetrates well into tissues, especially into the lungs, tonsils, and prostate, as well as into neutrophils and monocytes, stimulating their phagocytic activity. Plasma protein binding is 96%, decreasing when the roxithromycin concentration increases above 4 mg/L. Less than 0.05% of the administered dose is excreted in breast milk.
It is partially metabolized in the liver; more than half of the active substance is excreted in the feces unchanged; about 12% is excreted by the kidneys and about 15% by the lungs. T1/2 in adults with normal renal function is 10.5 hours when administered 1-2 times daily.
Indications
Infectious and inflammatory diseases caused by microorganisms sensitive to roxithromycin, including infections of the upper and lower respiratory tract, skin and soft tissue infections, non-gonococcal urethritis.
ICD codes
| ICD-10 code | Indication |
| J01 | Acute sinusitis |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J15.7 | Pneumonia due to Mycoplasma pneumoniae |
| J16.0 | Pneumonia due to chlamydia |
| J20 | Acute bronchitis |
| J31.0 | Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis) |
| J31.2 | Chronic pharyngitis |
| J32 | Chronic sinusitis |
| J35.0 | Chronic tonsillitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| N34 | Urethritis and urethral syndrome |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| ICD-11 code | Indication |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1C44 | Non-pyogenic bacterial infections of skin |
| CA01 | Acute rhinosinusitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA09.0 | Chronic rhinitis |
| CA09.2 | Chronic pharyngitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.00 | Pneumonia due to Chlamydophila pneumoniae |
| CA40.04 | Pneumonia due to Mycoplasma pneumoniae |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| EA50.3 | Staphylococcal scarlet fever |
| EB21 | Pyoderma gangrenosum |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Tablets
Orally for adults – 150 mg twice daily (every 12 hours) or 300 mg once daily 15 minutes before meals or on an empty stomach.
For patients with hepatic insufficiency, the dose is 150 mg every 24 hours.
For patients with severe renal insufficiency, the recommended dose is 150 mg every 24 hours.
For children, the daily dose is 5-8 mg/kg, depending on the type of pathogen and the severity of the infectious process, divided into 2 doses.
Adverse Reactions
From the digestive system: nausea, vomiting, epigastric pain, diarrhea, anorexia, flatulence, transient increase in the level of liver transaminases and alkaline phosphatase in the blood (more often in patients over 65 years old); rarely – impaired liver function, cholestatic hepatitis, pancreatitis.
Allergic reactions: urticaria, rash, itching, angioneurotic edema, bronchospasm, anaphylactoid reactions, tongue edema, general edema, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome.
From the central and peripheral nervous system: headache, dizziness, paresthesia.
Effects due to chemotherapeutic action: rarely – candidiasis.
Other: rarely – general malaise, tinnitus, disturbances in taste and/or smell.
Contraindications
Severe liver dysfunction, simultaneous use of ergot alkaloids with vasoconstrictive effect, hypersensitivity to roxithromycin and other macrolides (including erythromycin).
Use in Pregnancy and Lactation
Adequate and strictly controlled studies on the safety of roxithromycin use during pregnancy and lactation have not been conducted.
Roxithromycin is excreted in small amounts in breast milk.
In experimental studies on animals, no mutagenic or embryotoxic effects, or negative effects on fertility were identified.
Use in Hepatic Impairment
Contraindicated in severe liver dysfunction. Use with caution in patients with mild to moderate liver dysfunction.
Use in Renal Impairment
Use with caution in patients with impaired renal function.
Pediatric Use
Use is possible according to the dosing regimen.
Special Precautions
Use with caution in patients with impaired liver and kidney function.
If superinfection or pseudomembranous colitis develops, Roxithromycin should be immediately discontinued and appropriate therapy prescribed.
Use with caution simultaneously with terfenadine and astemizole.
In experimental studies, no carcinogenic effect was identified.
Drug Interactions
With simultaneous use with indirect anticoagulants, an enhancement of the anticoagulant effect is possible.
With simultaneous use with ergot preparations, ergotamine-like vasoconstrictive agents, the development of ergotism up to necrosis of limb tissues is possible.
With simultaneous use with digoxin, the absorption of digoxin increases.
With simultaneous use, a slight increase in the plasma concentrations of midazolam and triazolam is possible.
With simultaneous use with theophylline, an increase in the plasma concentration of theophylline is possible.
The possibility of an increase in plasma concentrations of cisapride, astemizole, terfenadine when used simultaneously with roxithromycin cannot be excluded.
With simultaneous use with cyclosporine, some increase in the blood concentration and toxic effect of cyclosporine is possible.
With simultaneous use with ethambutol, synergism against Mycobacterium avium is noted.
Storage Conditions
Store at 15°C (59°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Film-coated tablets, 150 mg: 10 or 20 pcs.
Marketing Authorization Holder
Sandoz, d.d. (Slovenia)
Manufactured By
S.C. Sandoz, S.r.L. (Romania)
Dosage Form
| Roxithromycin Sandoz® | Film-coated tablets, 150 mg: 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white, round, convex, with a smooth homogeneous surface, with a score on one side and the marking “R150” on the other.
| 1 tab. | |
| Roxithromycin | 150 mg |
Excipients: microcrystalline cellulose, povidone K30, poloxamer 188, magnesium stearate, isopropanol, purified water, titanium dioxide, hypromellose, PEG 400.
10 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (2) – cardboard packs.
Film-coated tablets, 300 mg: 7, 10, or 14 pcs.
Marketing Authorization Holder
Sandoz, d.d. (Slovenia)
Manufactured By
S.C. Sandoz, S.r.L. (Romania)
Dosage Form
| Roxithromycin Sandoz® | Film-coated tablets, 300 mg: 7, 10, or 14 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white, round, convex, with a smooth homogeneous surface, with a score on one side and the marking “R300” on the other.
| 1 tab. | |
| Roxithromycin | 300 mg |
Excipients: microcrystalline cellulose, povidone K30, poloxamer 188, magnesium stearate, isopropanol, purified water, titanium dioxide, hypromellose, PEG 400.
7 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (1) – cardboard packs.
14 pcs. – blisters (1) – cardboard packs.
Film-coated tablets, 50 mg: 10 or 20 pcs.
Marketing Authorization Holder
Sandoz, d.d. (Slovenia)
Manufactured By
S.C. Sandoz, S.r.L. (Romania)
Dosage Form
| Roxithromycin Sandoz® | Film-coated tablets, 50 mg: 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white, oblong, with a score on both sides, with a smooth homogeneous surface.
| 1 tab. | |
| Roxithromycin | 50 mg |
Excipients: microcrystalline cellulose, povidone K30, poloxamer 188, magnesium stearate, isopropanol, purified water, titanium dioxide, hypromellose, PEG 400.
10 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (2) – cardboard packs.
Tablets 150 mg: 10 or 20 pcs.
Marketing Authorization Holder
Dominanta-Service, JSC (Russia)
Manufactured By
Mekophar Chemical-Pharmaceutical, Joint Stock Company (Vietnam)
Dosage Form
| Roxithromycin DS | Tablets 150 mg: 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
Tablets white, round, biconvex in shape.
| 1 tab. | |
| Roxithromycin | 150 mg |
Excipients: lactose, corn starch, colloidal silicon dioxide, magnesium stearate.
10 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (2) – cardboard packs.
Film-coated tablets, 150 mg: 10 pcs.
Marketing Authorization Holder
Lek d.d. (Slovenia)
Dosage Form
| Roxithromycin LEK | Film-coated tablets, 150 mg: 10 pcs. |
Dosage Form, Packaging, and Composition
| Film-coated tablets | 1 tab. |
| Roxithromycin | 150 mg |
10 pcs. – contour cell blisters (1) – cardboard packs.
Film-coated tablets, 300 mg: 7 pcs.
Marketing Authorization Holder
Lek d.d. (Slovenia)
Dosage Form
| Roxithromycin LEK | Film-coated tablets, 300 mg: 7 pcs. |
Dosage Form, Packaging, and Composition
| Film-coated tablets | 1 tab. |
| Roxithromycin | 300 mg |
7 pcs. – contour cell blisters (1) – cardboard packs.
